{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.66","value":"140.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"Baseline SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.78","value":"-7.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"title":"Change from Baseline in SBP at Week 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.20","value":"88.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"title":"Baseline DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.98","value":"-5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"title":"Change from Baseline in DBP at Week 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Blood pressure was measured by 24-hour ABPM.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the mITT-OL Population who had HTN at Baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in SBP and DBP During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"mm Hg"}